Menu Search
Equities

Demant A/S

DEMANT:CPH

Demant A/S

Actions
Health CareMedical Equipment and Services
  • Price (DKK)258.00
  • Today's Change-1.60 / -0.62%
  • Shares traded272.51k
  • 1 Year change-7.29%
  • Beta1.4002
Data delayed at least 15 minutes, as of Nov 21 2024 16:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform8
Hold11
Sell2
Strong Sell0

Share price forecast in DKK

The 19 analysts offering 12 month price targets for Demant A/S have a median target of 285.00, with a high estimate of 360.00 and a low estimate of 245.00. The median estimate represents a 10.47% increase from the last price of 258.00.
High39.5%360.00
Med10.5%285.00
Low-5.0%245.00

Earnings history & estimates in DKK

Demant A/S reported annual 2023 earnings of 8.04 per share on Feb 05, 2024.
Average growth rate+20.00%
More ▼

Revenue history & estimates in DKK

Demant A/S had revenues for the full year 2023 of 22.44bn. This was 13.89% above the prior year's results.
Average growth rate+11.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.